• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, November 22, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

New Framework Clarifies How Natural Compounds Modulate DNA Damage Response Pathways

by
November 22, 2026
in Health
Reading Time: 6 mins read
0
New Framework Clarifies How Natural Compounds Modulate DNA Damage Response Pathways

New Framework Clarifies How Natural Compounds Modulate DNA Damage Response Pathways

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A comprehensive preclinical synthesis published in Archives of Pharmacal Research has established an evidence-stratified framework to evaluate how natural products interact with the cellular DNA damage response across major disease categories. Genomic stability in mammalian cells is continuously challenged by endogenous metabolic byproducts, including reactive oxygen species and aldehydes, as well as exogenous insults such as ionizing radiation, chemical toxins, and biological infections. When these lesions remain unrepaired, they trigger cellular mutations, chromosomal aberrations, premature senescence, or programmed cell death. Although a growing body of published pharmacological literature describes various plant-derived compounds, fungal extracts, and dietary phytochemicals as modifiers of genome maintenance, the researchers emphasize that experimental interpretations have long suffered from recurring mechanistic ambiguity. Many published investigations conflate indirect downstream reductions in oxidative stress, inflammation, and cellular injury markers with genuine, direct regulation of core enzymatic targets within the DNA repair machinery.

To establish rigorous mechanistic clarity, the review outlines the primary functional architecture governing canonical DNA damage response signaling networks. This surveillance apparatus functions across three coordinated stages: damage sensing, signal transduction, and repair execution. Sensing relies on phosphoinositide three-kinase-related kinases, specifically ataxia telangiectasia mutated, ataxia telangiectasia and Rad3-related, and the DNA-dependent protein kinase catalytic subunit. Double-strand breaks are recognized by ataxia telangiectasia mutated alongside the MRE11-RAD50-NBS1 complex, while DNA-dependent protein kinase partners with the Ku70 and Ku80 heterodimer to mediate non-homologous end joining. Concurrently, replication fork stalling and single-stranded DNA structures recruit the replication protein A-ATRIP complex to activate ataxia telangiectasia and Rad3-related kinase. These upstream sensors phosphorylate downstream mediator kinases, including checkpoint kinase one and checkpoint kinase two, and modify histone H2AX to generate phosphorylated gamma-H2AX foci that assemble repair complexes at damage sites while arresting the cell cycle to permit structural repair.

To evaluate natural compounds against this complex molecular network, the authors devised a four-tier evidence classification that separates direct target engagement from indirect physiological associations. Tier 1 requires direct biophysical or biochemical compound-target engagement corroborated by pathway-specific functional or causal genetic validation. Tier 2 encompasses target-linked or pathway-functional evidence that lacks complete direct-target binding or genetic rescue validation. Tier 3 designates in vivo or combined in vitro and in vivo demonstrations of repair-capacity preservation or defined signaling regulation occurring without direct target validation. Tier 4 represents purely in vitro, ex vivo, computational, or marker-level observations, such as isolated fluctuations in reactive oxygen species, gamma-H2AX levels, apoptosis rates, or single-time-point comet assays. Complementing these tiers, the authors organize functional outcomes into three operational categories: repair enhancement supported by functional lesion removal assays, stress mitigation reflecting upstream reduction of genotoxic insults, and signal homeostasis denoting contextual normalization of checkpoint or inflammatory signaling.

Preclinical oncology provides the most rigorously validated examples of direct Tier 1 and Tier 2 natural product interactions, largely centered on repair inhibition and synthetic lethality. In cancer therapeutics, impairing hyperactive repair pathways selectively eliminates malignant cells or sensitizes them to cytotoxic therapy. Classic natural leads illustrate this principle: camptothecin stabilizes topoisomerase I-DNA cleavage complexes, whereas novobiocin acts as a direct catalytic inhibitor of DNA polymerase theta ATPase activity, exploiting vulnerabilities in homologous recombination-deficient tumors. Resveratrol demonstrates direct biochemical inhibition of poly(ADP-ribose) polymerase 1 catalytic activity, and curcumin has been shown to downregulate BRCA2 expression and impair RAD51 focus formation, successfully generating an operational homologous recombination-deficient phenotype that heightens tumor sensitivity to poly(ADP-ribose) polymerase inhibitors. Other compounds induce lethal genotoxic stress, such as chaetocin provoking nuclear DNA fragmentation and G2/M arrest, and wogonin prolonging post-irradiation gamma-H2AX foci retention by suppressing double-strand break repair.

In non-malignant fibrotic conditions, pathological progression is frequently driven by chronic DNA damage response overactivation rather than intrinsic repair deficiency. Persistent cellular stress stimulates a self-sustaining loop wherein unresolved DNA lesions activate ataxia telangiectasia mutated and Rad3-related kinases alongside nuclear factor kappa B and STAT3 signaling, promoting myofibroblast differentiation and extracellular matrix accumulation. Furthermore, mitochondrial damage and subsequent oxidized mitochondrial DNA leakage trigger innate immune cascades through cyclic GMP-AMP synthase and stimulator of interferon genes activation. Natural products in this space function predominantly through Tier 2 or Tier 3 mechanisms by interrupting this inflammatory remodeling cycle. For example, taxifolin binds directly to N-myc downstream-regulated gene 1 to inhibit its phosphorylation at threonine 328, significantly lowering gamma-H2AX, HMGB1, and collagen deposition in carbon tetrachloride-induced liver fibrosis models, while parishin downregulates CD38 and activates SIRT1 to suppress senescence and fibrosis in aged lung tissue.

During ischemia-reperfusion injury, surging reactive oxygen species generate extensive nuclear and mitochondrial DNA damage, triggering toll-like receptor 9 activation and sterile inflammation. Vascular smooth muscle cells exposed to DNA damage undergo phenotypic switching from a contractile state to a synthetic, proliferative state driven by checkpoint kinase 1 phosphorylation, accelerating intimal hyperplasia and arterial stenosis. Preclinical studies indicate that ginsenoside Rd upregulates base excision repair glycosylases NEIL1 and NEIL3, diminishing both nuclear and mitochondrial DNA lesions following cerebral ischemia. Similarly, apigenin attenuates gamma-H2AX induction and DNA fragmentation in ischemic stroke models, while Taohong Siwu Decoction suppresses microvascular DNA damage, curbing AIM2 and NLRC4 inflammasome assembly, caspase-1 activation, and downstream interleukin-1beta release.

Reproductive disorders and gamete senescence represent an additional pathological domain where genomic maintenance is paramount, yet existing natural product studies predominantly occupy Tier 3 and Tier 4 evidence levels. Mature spermatozoa and developing oocytes rely on strict genomic surveillance to avoid transmitting chromosomal abnormalities or experiencing early embryonic arrest. In male reproductive models, exposure to environmental toxins or varicocele induces single- and double-strand breaks that correlate with reduced sperm concentration and motility. Administering lycopene or quercetin in experimental varicocele and cryopreserved asthenozoospermic semen mitigates malondialdehyde levels, reduces reactive oxygen species, and diminishes sperm DNA fragmentation. Ferulic acid and apigenin preserve oocyte developmental competence primarily by safeguarding mitochondrial membrane potential, sustaining intracellular ATP production, and upregulating SIRT1 expression rather than engaging specific meiotic repair components directly.

In the context of chronological aging and stem cell exhaustion, the progressive decline of cellular repair efficiency causes irreversible somatic mutation accumulation and functional deterioration. Genetic mouse models lacking the repair endonuclease ERCC1 develop severe progeroid phenotypes, systemic degeneration, and premature mortality, mirroring normal age-related pathology. Natural products investigated in anti-aging models predominantly mediate stress mitigation and cellular signaling homeostasis. Ginsenoside Rg1 reduces 8-hydroxy-2′-deoxyguanosine and gamma-H2AX accumulation in hematopoietic stem and progenitor cells, downregulating p16Ink4a-Rb and p53-p21 senescence cascades to restore clonogenic potential. In human clinical trials, oral supplementation with Monarda didyma extracts was associated with leukocyte telomere length maintenance and stabilization of epigenetic DNA methylation age, though the authors caution that these surrogate biomarker shifts require further causal validation.

Beyond direct catalytic inhibition or broad antioxidant effects, natural products exert multifaceted regulatory control over genome maintenance through epigenetic and RNA-mediated mechanisms. Furthermore, non-coding regulatory RNAs are increasingly recognized as modulators of homologous recombination and non-homologous end joining balance. Repair pathway choice is also modulated at the level of end resection, where compounds targeting nucleases such as CtIP, MRE11, and EXO1 dictate whether cells commit to high-fidelity homologous recombination or error-prone microhomology-mediated end joining.

The review deliberately highlights contradictory, paradoxical, and toxicological findings to counter the prevailing misconception that natural origin guarantees therapeutic safety or uniform pathway activation. Because natural products often possess pleiotropic, polypharmacological properties, their biological effects vary dramatically depending on chemical concentration, exposure duration, metabolic transformation, and genetic background. Extracts from Withania somnifera simultaneously alter multiple conflicting cascades, including Akt, nuclear factor kappa B, and caspase signaling, complicating precise target attribution. More critically, certain natural compounds display direct genotoxic liabilities: black cohosh extract and its constituent actein induce oxidative DNA damage, checkpoint activation, and chromosomal aberrations in mammalian systems. Similarly, areca nut preparations containing lime modify histone H3 to upregulate the securin proto-oncogene, driving chromosomal instability, while endophytic fungal extracts from Garcinia cowa trigger double-strand breaks that force error-prone non-homologous repair, potentially facilitating survival of mutagenized cells under specific cellular contexts.

Translating preclinical natural product discoveries into validated clinical interventions faces substantial pharmacological hurdles, including poor aqueous solubility, rapid metabolic clearance, low oral bioavailability, and unpredictable drug-drug interactions. Crude botanical extracts and multi-component formulas present batch-to-batch chemical heterogeneity that impedes reproducible target engagement, contrasting sharply with pure synthetic leads. To advance the discipline, the authors present a structured translational roadmap prioritizing target-guided drug discovery around validated synthetic lethality nodes, specifically DNA polymerase theta, Werner syndrome ATP-dependent helicase, and ubiquitin-specific peptidase 1. Future research must replace static, marker-only assays with dynamic live-cell imaging, spatial transcriptomics, and patient-derived organoid models capable of capturing temporal DNA damage dynamics. By systematically pairing rigorous exposure-response measurements with genetic rescue validation, investigators can transition natural products from non-specific antioxidant supplements into precise, evidence-based molecular probes and targeted therapeutic leads.

Subject of Research: Preclinical evidence framework evaluating natural products targeting the DNA damage response across human disease models

Article Title: Targeting the DNA damage response networks in disease: mechanistic insights and preclinical therapeutic potential of natural products

Article References: Song, L.-Y., Wang, Y.-Y., Fu, Y.-J., Li, W.-Y., Li, T.-G., Wang, Y., Wu, S.-J., Li, L., Qiu, Y., & Yang, Z.-S. (2026). Targeting the DNA damage response networks in disease: mechanistic insights and preclinical therapeutic potential of natural products. Archives of Pharmacal Research. https://doi.org/10.1007/s12272-026-01639-4

Image Credits: AI Generated

DOI: 10.1007/s12272-026-01639-4

Keywords: DNA damage response, natural products, ATM kinase, ATR kinase, DNA repair, synthetic lethality, genomic stability, PARP1 inhibition, polymerase theta, fibrosis, cerebral ischemia, cellular senescence, base excision repair, homologous recombination, preclinical pharmacology, translational medicine

News Source: Ophelia Keating. (November 22, 2026). New Framework Clarifies How Natural Compounds Modulate DNA Damage Response Pathways. Scienmag.

Tags: ATM kinaseATR kinasebase excision repairCellular SenescenceCerebral ischemiaDNA damage responseDNA RepairFibrosisgenomic stabilityhomologous recombinationnatural productsPARP1 inhibitionpolymerase thetaPreclinical PharmacologySynthetic lethalitytranslational medicine
Share12Tweet7Share2ShareShareShare1

Related Posts

High-Density Microwell Array Tracks Glioblastoma Clonal Expansion States at Single-Cell Resolution

High-Density Microwell Array Tracks Glioblastoma Clonal Expansion States at Single-Cell Resolution

November 22, 2026
Dairy Polar Lipids Reshape Piglet Gut Microbiomes and Circulating Lipid Mediators

Dairy Polar Lipids Reshape Piglet Gut Microbiomes and Circulating Lipid Mediators

November 22, 2026

Pangenome Graph Pipelines Miss Many Structural Inversions in Real Human Genomes

November 22, 2026

Corticosteroid Injections Provide Only Short-Term Relief for Greater Trochanteric Pain Syndrome

November 22, 2026

POPULAR NEWS

  • High-Density Microwell Array Tracks Glioblastoma Clonal Expansion States at Single-Cell Resolution

    High-Density Microwell Array Tracks Glioblastoma Clonal Expansion States at Single-Cell Resolution

    29 shares
    Share 12 Tweet 7
  • Dairy Polar Lipids Reshape Piglet Gut Microbiomes and Circulating Lipid Mediators

    29 shares
    Share 12 Tweet 7
  • Pangenome Graph Pipelines Miss Many Structural Inversions in Real Human Genomes

    29 shares
    Share 12 Tweet 7
  • Corticosteroid Injections Provide Only Short-Term Relief for Greater Trochanteric Pain Syndrome

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Prescribed-Time Controller Enforces Exact Convergence and Bounds for Robotic Exoskeleton Tracking

High-Density Microwell Array Tracks Glioblastoma Clonal Expansion States at Single-Cell Resolution

Dairy Polar Lipids Reshape Piglet Gut Microbiomes and Circulating Lipid Mediators

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.